Is CABA Worth Buying in 2026?

Cabaletta Bio, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-04-19

Here’s whether Cabaletta Bio, Inc. Common Stock (CABA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.02% over 10 days); strong 1-year return of +218.5%; 3-month momentum positive (+56.4%). Concerns: RSI 76 — overbought, elevated pullback risk. Currently 9.0% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

CABA is in a confirmed uptrend, trading above both its 50-day ($3.03) and 200-day ($2.37) moving averages. With an RSI of 76.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +218.5% compares to +35.1% for SPY (beat the market by 183.4%).

$10,000 invested 1 year ago → $31,852 today
vs. S&P 500 (SPY) — same period beat market by 183.4%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($2.37)
Above 50-day MA ($3.03)
!RSI(14) neutral zone (30–70) — currently 76.4
Positive return (+218.5%)
Within 10% of period high (−9.0%)
Period Range $3.44
$1.06 $3.78
RSI (14) 76.4
0 · OversoldOverbought · 100

Key Metrics

Price$3.44
Period Return+218.5%
Period High$3.78
Period Low$1.06
Drawdown−9.0%
MA-50$3.03
MA-200$2.37
RSI (14)76.4
Avg Volume (30d)1.9M
vs. SPYbeat by 183.4%
Return Rank#91 of 996

Trade CABA

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers